Understanding 'global' systems biology: Metabonomics and the continuum of metabolism

Nature Reviews Drug Discovery

Volumn 2, Issue 8, 2003, Pages 668-676

  Nicholson, Jeremy K ^a   Wilson, Ian D ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL; PROBIOTIC AGENT; XENOBIOTIC AGENT;

CELL ACTIVITY; CELL TYPE; DISEASE ACTIVITY; DISEASE COURSE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROBABILITY; REVIEW; ANIMAL; BIOLOGICAL MODEL; GENOMICS; METABOLISM;

ANIMALS; GENOMICS; HUMANS; MODELS, BIOLOGICAL; XENOBIOTICS;

EID: 0043069547     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1157     Document Type: Review

References (60)

1. Hood, L. & Galas, D. The digital code of DNA. Nature 421, 444-448(2003).
2. Smith, L. L. Key challenges for toxicologists in the 21st Century. Trend. Pharm. Sci. 22, 281-285 (2001).
3. Raamsdonk, L. M. et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nature Biotech. 19, 45-50(2001).
4. Gygi, S. P., Rochon, Y., Franza, B. R. & Aebersold, R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720-1730 (1999).
5. Nicholson, J. K., Lindon, J. C. & Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR data. Xenobiotica 29, 1181-1189 (1999).
6. Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153-161 (2002).
7. Lindon, J. C., Nicholson, J. K., Holmes, E. & Everett, J. R. Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn. Reson. 12, 289-320(2000).
8. 1H NMR-based metabonomics. Nature Med. 8, 1439-1444 (2002).
9. KEGG: Kyoto Encyclopaedia of genes and genomes. Release 26. April 2003.
10. Kacser, H. Recent developments beyond metabolic control analysis. Biochem. Soc. Trans. 23, 387-391 (1973).
11. Kacser, H. & Burns, J. A. in Rate Control of Biological processes. Symposium of the Society of Experimental Biology 27 (ed. Davies, D. D.) 65-104 (Cambridge Univ. Press, 1973).
12. Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
13. Srivastava, P. Drug metabolism and individualized medicine. Curr. Drug Metab. 4, 33-44 (2003).
14. Ingelman-Sundberg, M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181, 447-452 (2002).
15. Eichelbaum, M. & Burk, O. CYP3A genetics in drug metabolism. Nature Med. 7, 285-288 (2001).
16. Eiselt, R. et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458 (2001).
17. Scott, R. J. et al. Association of extracolonic manifestations of familial adenomatous polyposis with acetylation phenotype in a large FAP kindred. Eur. J. Hum. Genet. 5, 43-49 (1997).
18. Kivistö K. T. et al. Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 7, 295-302 (1997).
19. Griese, E. U., Asante-Poku, S., Ofori-Adjei D., Mikus, G. & Eichelbaum, M. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a west African population. Pharmacogenetics 9, 715-723 (1999).
20. Griese, E. U. et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from Western Australia. Pharmacogenetics 11, 69-76 (2001).
21. Gilmore, M. S. & Ferretti, J. J. The thin line between gut commensal and pathogen. Science 299,1999-2002 (2003).
22. Tannock, G. W. Normal Microflora (Chapman and Hall, 1995).
23. Xu, J. et al. A genomic, view of the human-Bacteroides thetaiotaomicron symbiosis. Science 299, 2074-2076 (2003).
24. Beale, B. Probiotics: Their tiny worlds are under scrutiny. The Scientist 16, 20-22 (2002).
25. Kirjavainen, P. V. et al. Aberrant composition of gut microflora of allergic infants: a target of bifidobacterial therapy at weaning. Gut 51, 51-55 (2002).
26. Muller, M. & Kersten, S. Nutrigenomics: Goals and Strategies. Nature Gen. 4, 315-322 (2003).
27. Willet, W. C. Balancing life-style and genomics research for disease prevention. Science 296, 695-698 (2002).
28. Ghauri, F., McLean, A., Beales, D., Wilson, I. D. & Nicholson, J. K. Induction of 5-oxoprolinuria in the rat following chronic feeding with N-acetyl 4-aminophenol (paracetamol). Biochem. Pharmacol. 46, 953-957 (1993).
29. Nyhan, W. L. & Ozand, P. T. Atlas of Metabolic Diseases (Chapman and Hall, 1998).
30. Lof, A. et al. Relationship between uptake and elimination of toluene and debrisoquine hydroxylation polymorphism. Clin. Pharmacol. Ther. 47, 412-417 (1990).
31. Cok, I., Dagdelen, A. & Gokce, E. Determination of urinary hippuratic acid and O-cresol levels as biological indicators of toluene exposure in shoe-workers and glure sniffers. Biomarkers 8, 119-127 (2003).
32. Phipps, A. N., Stewart, J., Wright, B. & Wilson, I. D. Effect of diet on the urinary excretion of hippuric acid and other dietary derived aromatics in the rat. Xenobiotica 28, 527-537 (1998).
33. Gavaghan, C. L. et al. HPLC-NMR spectroscopic and chemometric studies on metabolic variation in Sprague Dawley rats. Anal. Biochem. 291, 245-252 (2001).
34. Murphy, G. M. The Bile Acids Vol. 4 (eds. Katchevsky, D. K. & Nair, P. P.) (Plenum, 1988).
35. Setchell, K. D., Harrison, D. L., Gilbert, J. M. & Mupthy, G. M. Serum unconjugated bile acids: qualitative and quantitative profiles in ileal resection and bacterial overgrowth. Clin. Chim. Acta 152, 297-306 (1985).
36. Yoneda, M. et al. The biotransformed metabolite profiles in blood after intravenous administration of dehydrocholic acid. Am. J. Gastroenterol. 84, 290-295 (1989).
37. Einarsson, K., Nilsell, K. & Bjorkhem, I. Increased oxidoreduction of deoxycholic acid in cholecystectomised patients. Gut 30, 1275-1278 (1989).
38. Howard, P. J. & Murphy, G. M. Bile physiology: theory and practise. Curr. Opin. Gastroenterol. 6, 657-667 (1990).
39. Nicholls, A. N., Mortishire-Smith, R. & Nicholson, J. K. Metabonomic investigations into the acclimatisation of axenic rats to a normal gut microflora. Chem. Res. Toxicol. (in the press).
40. Krebs, H. A. & Perkins, J. R. The physiological role of liver alcohol dehydrogenase.Biochem. J. 118, 635-644 (1970).
41. Albro, P. W. & Lavenhar, S. R. Metabolism of di (2-ethylhexyl)phthalate. Drug Metab. Rev. 21, 13-34 (1989).
42. Astill, B. D. Metabolism of DEHP: Effects of prefeeding and dose variation, and comparative studies in rodents and the cynomolgus monkey (CMA Studies). Drug Metab. Rev. 21, 35-53(1989).
43. Wilson, I. D. & Nicholson, J. K. Do metabolic pathways for xenobiotics really exist? Xenobiotica (in the press).
44. Schwartz, M. A. Chemical aspects of penicillin allergy. J. Pharm. Sci. 58, 643-661 (1969).
45. 1H NMR spectroscopic studies of the metabolism and excretion of ampicillin and amoxycillin. J. Pharm. Pharmacol. 46, 128-134 (1994).
46. Nicholson, J. K. et al. Proton NMR studies of serum, plasma and urine from fasting normal, and diabetic subjects. Biochem. J. 217, 365-375 (1984),
47. Caldwell, J., Hutt, A. J., Marsh, M. V. & Sinclair, K. in Drug Metabolite Isolation and Determination (eds Reid, E. & Leppard, J. P.) 161-179 (Plenum, New York, 1983).
48. Corcoran, O., Mortensen, R. W., Hansen, S. H., Troke, J. & Nicholson, J. K. HPLC/1H NMR spectroscopic studies of the reactive α-1-O-acyl isomer formed during acyl migration of S-naproxen β-1-O-acyl glucuronide. Chem. Res. Toxicol. 14, 1363-1370 (2001).
49. 1H NMR and HPLC-UV. Drug Metab. Dispos. 29, 375-380 (2001).
50. Nicholls, A. W. et al. NMR spectroscopic and theoretical chemistry studies on the internal acyl migration reactions of the 1-O-acyl-β-glucopyranuronate conjugates of 2-, 3- and 4-trifluoromethylbenzoic acids. Chem. Res. ToxicoL 9, 1414-1424 (1996).
51. Spahn-Langguth, H. & Benet, L. Z. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev. 24, 5-48 (1992).
52. 1H NMR spectroscopic studies on the reactions of haloalkylamines with bicarbonate ions: Formation of N-carbamates and 2-oxazolidone in cell culture media and blood plasma. Chem. Res. Toxicol. 8, 1046-1053 (1995).
53. Holmes, E. et al. Quantitative structure metabolism relationships and the prediction of phase II conjugation reactions of substituted phenols in the rat. Xenobiotica 25, 1269-1282(1995).
54. Ghauri, F. Y. K. et al. Quantitative structure metabolism relationships for substituted benzoic acids in the rat using NMR spectroscopy, computational chemistry and pattern recognition methods. Biochem. Pharmacol. 44, 1935-1946(1992).
55. Cupid, B. C., Bedell, C. R., Lindon, J. C., Wilson, I. D. & Nicholson, J. K. Quantitative structure metabolism relationships for substituted benzoic acids in the rabbit: prediction of urinary excretion of glycine and glucuronide conjugates. Xenobiotica 26, 157-176(1996).
56. Scarfe, G. B., Wilson, I. D., Lindon, J. C., Holmes, E. & Nicholson, J. K. Determination of structure-metabolism relationships of substituted anilines for prediction of N-acetylation and N-oxanillic acid formation. Xenobiotica 32, 267-277(2002).
57. Nicholson, J. K. et al. High-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry (HPLC-ICP-MS) and orthogonal acceleration time-of-flight mass spectrometry (oa-TOF-MS) for the simultaneous analysis and identification of the metabolites of 2-bromo-4-trifluoromethylacetaniline in rat urine. Anal. Chem. 73, 1491-1494 (2001).
58. Major, H., Castro-Perez, J., Nicholson, J. K. & Wilson, I. D. Characterisation of putative pentose-containing conjugates as minor metabolites of 4-bromoaniline presenting the urine of rats following intraperitoneal administration. Rap. Comm. in Mass Spectrom. 17, 76-80 (2003).
59. Skilling, J. in Maximum Entropy and Bayesian Methods (ed. Paul Fougere) 267-273 (Kluwer, Dordrecht, 1990).
60. Seddon, M. J., Spraul, M., Wilson, I. D., Nicholson, J. K. & Lindon, J. C. Improvement in the characterization of minor drug metabolites from HPLC-NMR studies through the use of quantified maximum entropy processing of NMR spectra. J. Pharm Biomed. Anal. 12, 419-424 (1994).